Treatment of b-lymphocyte proliferative disorders includes drug therapy, stem cell transplantation therapy, chemotherapy, and radiation therapy, depending on the cause of the disease, which is described below in terms of three common disorders, including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and chronic lymphoblastic leukemia. The b-lymphocyte proliferative diseases may include: 1. acute lymphoblastic leukemia type B: the most common, according to the severity can be divided into 3 groups: low-risk, intermediate-risk and high-risk. (1) Patients in the low-risk and intermediate-risk groups should first be given to undergo induced remission therapy, VDLP is the commonly used program (vincristine + Zoerythromycin + levodopa montelukastase + prednisone), and after remission, they should undergo maintenance and consolidation therapy with methotrexate and 6-mercaptopurine, and at the same time, they need to do lumbar puncture plus intrathecal injection of drug therapy. (2) For patients in the high-risk group, the induction of remission at the beginning is the same as that of patients in the low- and intermediate-risk groups, but other chemotherapeutic drugs, such as cedarbenzamide, can be added according to the needs of the disease. After induction of remission, allogeneic hematopoietic stem cell transplantation should be performed as soon as possible if available; those who are not eligible for bone marrow transplantation should be treated with high-dose methotrexate maintenance therapy, and lumbar puncture with intrathecal drug injection is also needed. 2. Diffuse large B-cell lymphoma: chemotherapy, bio-immunotherapy and radiotherapy can be given. The first-line regimen is rituximab combined with a cho protocol (cyclophosphamide, adriamycin, vincristine, prednisone). 3. Chronic lymphocytic leukemia: drug therapy (nitrogen mustard phenylbutyrate, fludarabine, rituximab), hematopoietic stem cell transplantation, radiation therapy, etc. can be given. If diagnosed with b-lymphocyte proliferative disease, it is recommended to standardize the treatment as early as possible under the guidance of a physician, and not to use medication on your own in order to reduce the adverse effects of the disease.